Corvus Pharmaceuticals, Inc. (CRVS): Shareholders' Equity
$61.20M
As of 2025-12-31
$225.33M
As of 2026-06-30
+2.9%
3-year compound annual growth
-3.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.20M | +87.9% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $32.57M | -15.8% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $38.68M | -31.1% | 2026-03-12, Balance as of period end |
| 2022-12-31 | $56.12M | -42.2% | 2025-03-25, Balance as of period end |
| 2021-12-31 | $97.16M | +34.7% | 2024-03-19, Balance as of period end |
| 2020-12-31 | $72.15M | +1.5% | 2023-03-28, Balance as of period end |
| 2019-12-31 | $71.11M | -35.6% | 2022-03-10, Balance as of period end |
| 2018-12-31 | $110.34M | +30.1% | 2021-03-25, Balance as of period end |
| 2017-12-31 | $84.83M | -36.1% | 2020-03-09, Balance as of period end |
| 2016-12-31 | $132.80M | n/m | 2019-03-07, Balance as of period end |
| 2015-12-31 | -$31.10M | n/m | 2018-03-01, Balance as of period end |
| 2014-12-31 | -$159.0K | n/a | 2017-03-10, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $61.20M | +87.9% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $44.25M | -37.7% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $24.80M | -66.2% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $59.02M | +28.0% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $60.47M | -36.5% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $24.10M | -64.8% |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $63.90M | -4.1% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $24.88M | +8.9% |
| Adagene Inc. (ADAG) | 2025-12-31 | $35.35M | -30.0% |
Compare CRVS, ALDX, HOWL, SPRO side by side · Screen every company in Pharmaceutical Preparations ↗